Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 30.66 Billion KRW | 7.22% |
| 2022 | 28.59 Billion KRW | -20.54% |
| 2021 | 35.98 Billion KRW | -5.64% |
| 2020 | 38.13 Billion KRW | 7.14% |
| 2019 | 35.59 Billion KRW | 22.74% |
| 2018 | 29 Billion KRW | -15.94% |
| 2017 | 34.5 Billion KRW | 4.26% |
| 2016 | 33.08 Billion KRW | -18.01% |
| 2015 | 40.36 Billion KRW | 14.12% |
| 2014 | 35.36 Billion KRW | 1.62% |
| 2013 | 34.8 Billion KRW | 0.07% |
| 2012 | 34.77 Billion KRW | -3.38% |
| 2011 | 35.99 Billion KRW | -16.22% |
| 2010 | 42.96 Billion KRW | 14.55% |
| 2009 | 37.5 Billion KRW | 13.34% |
| 2008 | 33.09 Billion KRW | 134.5% |
| 2007 | 14.11 Billion KRW | -7.73% |
| 2006 | 15.29 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 27.65 Billion KRW | -9.53% |
| 2024 Q1 | 30.56 Billion KRW | -0.32% |
| 2023 Q3 | 31.03 Billion KRW | -1.9% |
| 2023 Q4 | 30.66 Billion KRW | -1.2% |
| 2023 Q1 | 28.72 Billion KRW | 0.44% |
| 2023 Q2 | 31.63 Billion KRW | 10.14% |
| 2023 FY | 30.66 Billion KRW | 7.22% |
| 2022 Q1 | 36.18 Billion KRW | 0.56% |
| 2022 FY | 28.59 Billion KRW | -20.54% |
| 2022 Q4 | 28.59 Billion KRW | -7.75% |
| 2022 Q3 | 30.99 Billion KRW | -6.45% |
| 2022 Q2 | 33.13 Billion KRW | -8.43% |
| 2021 Q2 | 38.17 Billion KRW | -0.21% |
| 2021 Q1 | 38.25 Billion KRW | 0.31% |
| 2021 FY | 35.98 Billion KRW | -5.64% |
| 2021 Q4 | 35.98 Billion KRW | -5.51% |
| 2021 Q3 | 38.08 Billion KRW | -0.23% |
| 2020 Q1 | 33.85 Billion KRW | -4.89% |
| 2020 Q3 | 34.02 Billion KRW | 0.56% |
| 2020 Q4 | 38.13 Billion KRW | 12.09% |
| 2020 FY | 38.13 Billion KRW | 7.14% |
| 2020 Q2 | 33.83 Billion KRW | -0.06% |
| 2019 Q4 | 35.59 Billion KRW | 8.47% |
| 2019 FY | 35.59 Billion KRW | 22.74% |
| 2019 Q3 | 32.81 Billion KRW | -6.16% |
| 2019 Q2 | 34.96 Billion KRW | 5.38% |
| 2019 Q1 | 33.18 Billion KRW | 14.42% |
| 2018 Q4 | 29 Billion KRW | 0.0% |
| 2018 FY | 29 Billion KRW | -15.94% |
| 2018 Q1 | 33 Billion KRW | -4.35% |
| 2018 Q2 | 32 Billion KRW | -3.03% |
| 2018 Q3 | 29 Billion KRW | -9.38% |
| 2017 Q1 | 33.03 Billion KRW | -0.18% |
| 2017 FY | 34.5 Billion KRW | 4.26% |
| 2017 Q4 | 34.5 Billion KRW | 4.55% |
| 2017 Q3 | 33 Billion KRW | -0.0% |
| 2017 Q2 | 33 Billion KRW | -0.09% |
| 2016 Q3 | 33.07 Billion KRW | -13.12% |
| 2016 Q2 | 38.06 Billion KRW | -5.03% |
| 2016 Q1 | 40.08 Billion KRW | -0.69% |
| 2016 FY | 33.08 Billion KRW | -18.01% |
| 2016 Q4 | 33.08 Billion KRW | 0.06% |
| 2015 Q3 | 40.07 Billion KRW | -8.5% |
| 2015 Q2 | 43.79 Billion KRW | 2.18% |
| 2015 Q1 | 42.85 Billion KRW | 21.17% |
| 2015 FY | 40.36 Billion KRW | 14.12% |
| 2015 Q4 | 40.36 Billion KRW | 0.72% |
| 2014 Q3 | 34.32 Billion KRW | -1.99% |
| 2014 Q1 | 35.52 Billion KRW | 2.07% |
| 2014 Q4 | 35.36 Billion KRW | 3.05% |
| 2014 FY | 35.36 Billion KRW | 1.62% |
| 2014 Q2 | 35.01 Billion KRW | -1.42% |
| 2013 FY | 34.8 Billion KRW | 0.07% |
| 2013 Q2 | 33.12 Billion KRW | -1.08% |
| 2013 Q3 | 32.36 Billion KRW | -2.28% |
| 2013 Q4 | 34.8 Billion KRW | 7.52% |
| 2013 Q1 | 33.48 Billion KRW | -3.72% |
| 2012 Q1 | 34.46 Billion KRW | 0.0% |
| 2012 Q4 | 34.77 Billion KRW | 0.0% |
| 2012 FY | 34.77 Billion KRW | -3.38% |
| 2011 FY | 35.99 Billion KRW | -16.22% |
| 2011 Q1 | 42.96 Billion KRW | -4.11% |
| 2011 Q2 | 40.78 Billion KRW | -5.08% |
| 2011 Q3 | 36.55 Billion KRW | -10.37% |
| 2010 Q4 | 44.8 Billion KRW | -0.62% |
| 2010 FY | 42.96 Billion KRW | 14.55% |
| 2010 Q2 | 44.83 Billion KRW | 19.55% |
| 2010 Q3 | 45.08 Billion KRW | 0.55% |
| 2010 Q1 | 37.5 Billion KRW | -12.1% |
| 2009 FY | 37.5 Billion KRW | 13.34% |
| 2009 Q4 | 42.67 Billion KRW | 0.61% |
| 2009 Q3 | 42.41 Billion KRW | -1.85% |
| 2009 Q2 | 43.21 Billion KRW | 30.58% |
| 2009 Q1 | 33.09 Billion KRW | -8.51% |
| 2008 Q1 | 14.11 Billion KRW | -22.92% |
| 2008 Q2 | 20.36 Billion KRW | 44.33% |
| 2008 Q4 | 36.17 Billion KRW | 53.27% |
| 2008 Q3 | 23.59 Billion KRW | 15.86% |
| 2008 FY | 33.09 Billion KRW | 134.5% |
| 2007 Q2 | 18.4 Billion KRW | 0.0% |
| 2007 Q4 | 18.3 Billion KRW | 8.81% |
| 2007 FY | 14.11 Billion KRW | -7.73% |
| 2007 Q3 | 16.82 Billion KRW | -8.56% |
| 2006 FY | 15.29 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 22.192% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 95.568% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 91.975% |
| HANDOK Inc. | 300.01 Billion KRW | 89.78% |
| Yuhan Corporation | 230.07 Billion KRW | 86.673% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 92.461% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -5049.088% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 94.648% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -2275.93% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 63.995% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 29.142% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 66.113% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -15.562% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 22.192% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -12776.413% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 86.376% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 83.059% |
| JW Holdings Corporation | 554.58 Billion KRW | 94.471% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 85.925% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 86.048% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 81.993% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 33.562% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | 21.79% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 82.566% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 63.912% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 22.192% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 86.988% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 93.472% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 81.993% |
| Yuhan Corporation | 230.07 Billion KRW | 86.673% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 82.279% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 54.155% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 93.446% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 81.993% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 74.155% |
| Korea United Pharm Inc. | 40.33 Billion KRW | 23.989% |
| CKD Bio Corp. | 146.92 Billion KRW | 79.131% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 79.006% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 36.459% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -4751.4% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 33.562% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 93.449% |
| Boryung Corporation | 204.21 Billion KRW | 84.985% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 61.376% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 63.995% |
| JW Lifescience Corporation | 46.31 Billion KRW | 33.794% |